RESUMEN
PURPOSE: To evaluate the effects of prednisolone against sodium diclofenac both with ciprofloxacin compared to artificial tears on the symptoms and signs of acute viral conjunctivitis. METHODS: Study included 37 patients diagnosed with acute conjunctivitis and distributed by three groups: A (1% prednisolone acetate + ciprofloxacin (0.3%); B (Sodium diclofenac (0.1%) + ciprofloxacin (0.3%) and C (artificial tears + ciprofloxacin (0.3%). Patients received medication 6/6 hours daily. Signs and symptoms (e.g. lacrimation, burning, photophobia, etc.) were scored at baseline and on the first, third, fifth and seventh days and in the end of treatment using a standardized questionnaire and slit lamp anterior segment examination. RESULTS: All three groups demonstrated an improvement in the signs and symptoms of conjunctivitis in their follow-up visits. There was no significant difference in symptom and sign scores between Group A and B and B and C in the study visits ( p >0.05). However, the comparison between groups A and C showed a clinical trend (p=0.05) on third evaluation suggesting better clinical action using the corticosteroids. CONCLUSION: The prednisolone acetate was not superior to the use of sodium diclofenac or artificial tears in relieving the signs and symptoms of viral conjunctivitis.
Asunto(s)
Corticoesteroides/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Ciprofloxacina/administración & dosificación , Conjuntivitis Viral/tratamiento farmacológico , Diclofenaco/administración & dosificación , Prednisolona/análogos & derivados , Enfermedad Aguda , Adolescente , Adulto , Anciano , Análisis de Varianza , Femenino , Humanos , Interferón gamma , Interleucinas/análisis , Gotas Lubricantes para Ojos/administración & dosificación , Masculino , Persona de Mediana Edad , Óxido Nítrico Sintasa/análisis , Soluciones Oftálmicas/administración & dosificación , Prednisolona/administración & dosificación , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/análisis , Adulto JovenRESUMEN
Calotropis procera (ushaar) produces a copious amount of latex, which has both inflammatory and anti-inflammatory pharmacological properties. Local application produces an intense inflammatory response and causes significant ocular morbidity. We report corneal toxicity following self-application of latex from C. procera in a 74-year-old man. He reported painless decreased vision in the affected eye with diffuse corneal edema, and specular microscopy revealed a reduced endothelial cell count. After he was treated with topical corticosteroids, his visual acuity improved from hand motion to 20/80. The composition of the active compounds in the latex was analyzed. When topically administered, the latex may cause severe ocular injuries and a loss of endothelial cells over a period of time. Public education, early recognition of such injuries, and timely intervention may prevent permanent ocular damage.
Asunto(s)
Calotropis/química , Edema Corneal/inducido químicamente , Látex/toxicidad , Trastornos de la Visión/inducido químicamente , Administración Oftálmica , Anciano , Córnea/efectos de los fármacos , Edema Corneal/diagnóstico , Edema Corneal/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Humanos , Masculino , Soluciones Oftálmicas , Fitoquímicos , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Autoadministración , Trastornos de la Visión/diagnóstico , Trastornos de la Visión/tratamiento farmacológico , Agudeza Visual/efectos de los fármacosRESUMEN
Abstract Purpose To evaluate the effects of prednisolone against sodium diclofenac both with ciprofloxacin compared to artificial tears on the symptoms and signs of acute viral conjunctivitis. Methods Study included 37 patients diagnosed with acute conjunctivitis and distributed by three groups: A (1% prednisolone acetate + ciprofloxacin (0.3%); B (Sodium diclofenac (0.1%) + ciprofloxacin (0.3%) and C (artificial tears + ciprofloxacin (0.3%). Patients received medication 6/6 hours daily. Signs and symptoms (e.g. lacrimation, burning, photophobia, etc.) were scored at baseline and on the first, third, fifth and seventh days and in the end of treatment using a standardized questionnaire and slit lamp anterior segment examination. Results All three groups demonstrated an improvement in the signs and symptoms of conjunctivitis in their follow-up visits. There was no significant difference in symptom and sign scores between Group A and B and B and C in the study visits ( p >0.05). However, the comparison between groups A and C showed a clinical trend (p=0.05) on third evaluation suggesting better clinical action using the corticosteroids. Conclusion The prednisolone acetate was not superior to the use of sodium diclofenac or artificial tears in relieving the signs and symptoms of viral conjunctivitis.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Prednisolona/análogos & derivados , Ciprofloxacina/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Conjuntivitis Viral/tratamiento farmacológico , Diclofenaco/administración & dosificación , Corticoesteroides/administración & dosificación , Soluciones Oftálmicas/administración & dosificación , Prednisolona/administración & dosificación , Enfermedad Aguda , Análisis de Varianza , Interleucinas/análisis , Interferón gamma , Factor de Necrosis Tumoral alfa/análisis , Resultado del Tratamiento , Óxido Nítrico Sintasa/análisis , Gotas Lubricantes para Ojos/administración & dosificaciónRESUMEN
Hyperglycemia significantly contributes to the development and progression of metabolic diseases. Managing postprandial blood glucose fluctuations is of particular importance for patients with hyperglycemia, but safe and effective means of reducing blood glucose levels are still lacking. Five diets with varying macronutrient ratios and omega-3 fatty acid amounts were tested for their blood glucose-lowering effects in male C57BL/6J mice. The diets with potent blood glucose-lowering effects were further investigated for their underlying mechanisms and their beneficial effects on hyperglycemia models. Mice given the low-carbohydrate, high-protein, and high-omega-3 (LCHP+3) diet exhibited a rapid reduction of the blood glucose levels that remained consistently low, regardless of feeding. These effects were associated with reduced amino acid gluconeogenesis, due to the inhibition of hepatic alanine transaminase (ALT). Furthermore, the LCHP+3 intervention was effective in reducing the blood glucose levels in several disease conditions, including type 1 diabetes mellitus, hormone-induced hyperglycemia, and diet-induced metabolic syndrome. Our findings identify the LCHP+3 diet as a potent blood glucose-lowering diet that suppresses postprandial blood glucose fluctuations through the inhibition of gluconeogenesis and may have great clinical utility for the management of metabolic diseases with hyperglycemia.
Asunto(s)
Diabetes Mellitus Experimental/dietoterapia , Dieta Baja en Carbohidratos , Dieta Rica en Proteínas , Ácidos Grasos Omega-3/administración & dosificación , Gluconeogénesis/efectos de los fármacos , Hiperglucemia/dietoterapia , Síndrome Metabólico/dietoterapia , Alanina/metabolismo , Alanina Transaminasa/metabolismo , Animales , Glucemia/metabolismo , Isótopos de Carbono , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/metabolismo , Dieta Occidental/efectos adversos , Modelos Animales de Enfermedad , Hiperglucemia/inducido químicamente , Hiperglucemia/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Síndrome Metabólico/etiología , Síndrome Metabólico/metabolismo , Ratones , Ratones Endogámicos C57BL , Periodo Posprandial , Prednisolona/análogos & derivados , EstreptozocinaRESUMEN
A urine metabolomics method based on gas chromatography-mass spectrometry was developed in order to investigate the metabolite characteristics of systemic lupus erythematosus (SLE) and the therapeutic effects of Jieduquyuziyin prescription. The urinary metabolic profiles in urine specimens of the SLE model mice (MRL/lpr) group, prednisone acetate-treated SLE mouse group, Jieduquyuziyin prescription-treated SLE mouse group, and control group (C57BL/6 J) after the administration were analyzed by gas chromatography-mass spectrometry. These metabolic profiles were then processed by multivariate analysis, in particular Mass Profiler Professional, SIMCA-P and partial least-squares discriminant analysis. According to the partial least-squares discriminant analysis results, the SLE model group and the control group were obviously separated, indicating that the incidence of SLE had a greater impact on the metabolic network, and the SLE model group had significant difference compared with the control group in urine metabolites. Eleven differential metabolites were identified to be related to SLE, and the results of differential metabolite identification showed that the metabolites were mainly related to energy metabolism and amino acid metabolism pathway. These results can provide an experimental basis for further exploring the mechanism of traditional Chinese medicine in the treatment of SLE.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Cromatografía de Gases y Espectrometría de Masas/métodos , Lupus Eritematoso Sistémico/metabolismo , Metaboloma/efectos de los fármacos , Compuestos Orgánicos/orina , Animales , Modelos Animales de Enfermedad , Femenino , Metabolómica/métodos , Ratones , Ratones Endogámicos C57BL , Compuestos Orgánicos/metabolismo , Prednisolona/análogos & derivados , Prednisolona/farmacología , Análisis de Componente PrincipalRESUMEN
Guedes-Pinto paste is the filling material most employed in Brazil for endodontic treatment of deciduous teeth; however, the Rifocort® ointment has been removed. Thus, the aim of this study was to investigate the antimicrobial potential of filling pastes, by proposing three new pharmacological associations to replace Rifocort® ointment with drugs of already established antimicrobial power: Nebacetin® ointment, 2% Chlorhexidine Gluconate gel, and Maxitrol® ointment. A paste composed of Iodoform, Rifocort® ointment and Camphorated Paramonochlorophenol (CPC) was employed as the gold standard (G1). The other associations were: Iodoform, Nebacetin® ointment and CPC (G2); Iodoform, 2% Chlorhexidine Digluconate gel and CPC (G3); Iodoform, Maxitrol® ointment and CPC (G4). The associations were tested for Staphylococcus aureus (S. aureus), Streptococcus mutans (S. mutans), Streptococcus oralis (S. oralis), Enterococcus faecalis (E. faecalis), Escherichia coli (E. coli), and Bacillus subtilis (B. subtilis), using the methods of dilution on solid medium - orifice agar - and broth dilution. The results were tested using statistical analysis ANOVA and Kruskal-Wallis. They showed that all the pastes had a bacteriostatic effect on all the microorganisms, without any statistically significant difference, compared with G1. S. aureus was statistically significant (multiple comparison test of Tukey), insofar as G2 and G3 presented the worst and the best performance, respectively. All associations were bactericidal for E. coli, S. aureus, S. mutans and S. oralis. Only G3 and G4 were bactericidal for E. faecalis, whereas no product was bactericidal for B. subtilis. Thus, the tested pastes have antimicrobial potential and have proved acceptable for endodontic treatment of primary teeth.
Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Materiales de Obturación del Conducto Radicular/farmacología , Diente Primario/efectos de los fármacos , Análisis de Varianza , Bacitracina/farmacología , Bacterias/crecimiento & desarrollo , Clorhexidina/análogos & derivados , Clorhexidina/farmacología , Combinación de Medicamentos , Fluprednisolona/farmacología , Pruebas de Sensibilidad Microbiana , Neomicina/farmacología , Pomadas , Polimixina B/farmacología , Prednisolona/análogos & derivados , Prednisolona/farmacología , Reproducibilidad de los Resultados , Rifamicinas/farmacología , Estadísticas no Paramétricas , Factores de TiempoRESUMEN
Guedes-Pinto paste is the filling material most employed in Brazil for endodontic treatment of deciduous teeth; however, the Rifocort® ointment has been removed. Thus, the aim of this study was to investigate the antimicrobial potential of filling pastes, by proposing three new pharmacological associations to replace Rifocort® ointment with drugs of already established antimicrobial power: Nebacetin® ointment, 2% Chlorhexidine Gluconate gel, and Maxitrol® ointment. A paste composed of Iodoform, Rifocort® ointment and Camphorated Paramonochlorophenol (CPC) was employed as the gold standard (G1). The other associations were: Iodoform, Nebacetin® ointment and CPC (G2); Iodoform, 2% Chlorhexidine Digluconate gel and CPC (G3); Iodoform, Maxitrol® ointment and CPC (G4). The associations were tested for Staphylococcus aureus (S. aureus), Streptococcus mutans (S. mutans), Streptococcus oralis (S. oralis), Enterococcus faecalis (E. faecalis), Escherichia coli (E. coli), and Bacillus subtilis (B. subtilis), using the methods of dilution on solid medium – orifice agar – and broth dilution. The results were tested using statistical analysis ANOVA and Kruskal-Wallis. They showed that all the pastes had a bacteriostatic effect on all the microorganisms, without any statistically significant difference, compared with G1. S. aureus was statistically significant (multiple comparison test of Tukey), insofar as G2 and G3 presented the worst and the best performance, respectively. All associations were bactericidal for E. coli, S. aureus, S. mutans and S. oralis. Only G3 and G4 were bactericidal for E. faecalis, whereas no product was bactericidal for B. subtilis. Thus, the tested pastes have antimicrobial potential and have proved acceptable for endodontic treatment of primary teeth.
Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Materiales de Obturación del Conducto Radicular/farmacología , Diente Primario/efectos de los fármacos , Análisis de Varianza , Bacitracina/farmacología , Bacterias/crecimiento & desarrollo , Clorhexidina/análogos & derivados , Clorhexidina/farmacología , Combinación de Medicamentos , Fluprednisolona/farmacología , Pruebas de Sensibilidad Microbiana , Neomicina/farmacología , Pomadas , Polimixina B/farmacología , Prednisolona/análogos & derivados , Prednisolona/farmacología , Reproducibilidad de los Resultados , Rifamicinas/farmacología , Estadísticas no Paramétricas , Factores de TiempoRESUMEN
Molecular docking studies were performed on 18 17ß-carboxamide steroids in order to select compounds with potential local anti-inflammatory activity. These derivatives are amides of cortienic acids (obtained from hydrocortisone, prednisolone, and methylprednisolone) with methyl or ethyl esters of six amino acids. Interactions with the glucocorticoid receptor (GR), binding energies and ligand efficiency values of these compounds were compared with dexamethasone and cortienic acid obtained from prednisolone (inactive metabolite). On the basis of molecular docking studies, seven compounds were selected and their binding affinities for the GR were predicted by use of the exponential model created in this study. Subsequently, selected compounds were synthesized in good yields by use of modified N,N'-dicyclohexylcarbodiimide (DCC)/1-hydroxybenzotriazole (HOBt) coupling procedure. Finally, the local anti-inflammatory activity of the synthesized compounds was examined by use of the croton oil-induced ear edema test. In vivo evaluation of systemic side effects as well as in silico prediction of metabolism were performed on the derivative with the best local anti-inflammatory activity. The combination of molecular docking studies and the exponential model for the GR binding affinity prediction could be used as an in silico tool for the rational design of novel 17ß-carboxamide steroids with potentially better biological profile than dexamethasone.
Asunto(s)
Antiinflamatorios/síntesis química , Antiinflamatorios/farmacología , Diseño de Fármacos , Edema/prevención & control , Glucocorticoides/síntesis química , Glucocorticoides/farmacología , Inflamación/prevención & control , Animales , Antiinflamatorios/metabolismo , Biotransformación , Aceite de Crotón , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Edema/inducido químicamente , Glucocorticoides/metabolismo , Hidrocortisona/análogos & derivados , Hidrocortisona/síntesis química , Hidrocortisona/metabolismo , Hidrocortisona/farmacología , Inflamación/inducido químicamente , Ligandos , Metilprednisolona/análogos & derivados , Metilprednisolona/síntesis química , Metilprednisolona/metabolismo , Metilprednisolona/farmacología , Modelos Biológicos , Simulación del Acoplamiento Molecular , Estructura Molecular , Prednisolona/análogos & derivados , Prednisolona/síntesis química , Prednisolona/metabolismo , Prednisolona/farmacología , Ratas , Receptores de Glucocorticoides/efectos de los fármacos , Receptores de Glucocorticoides/metabolismo , Relación Estructura-ActividadRESUMEN
INTRODUCTION: This study describes a case of eye burn induced by sodium hypochlorite used as an irrigant during root canal preparation. METHODS: A 24-year-old female endodontist was using an operating microscope during root canal treatment, and as the root canal was irrigated, the pressure cannula burst and the irrigant (3.5% sodium hypochlorite) came into direct contact with her left eye. She immediately sought ophthalmologic emergency care for pain, redness of the cornea, burning sensation, photophobia, intraocular pressure, and blurred vision. The initial treatment consisted of washing the eye with saline solution and administering analgesic and anti-inflammatory (steroid) medications. One day after the accident, a topical demulcent and hydroxypropyl medication were applied to the eyeball (conjunctiva), the eye was bandaged for 24 hours, and rest was prescribed for 7 days. Eight days later, a corneal ulcer was diagnosed, and antibiotic and anti-inflammatory (steroid) medications were used. RESULTS: Vision was restored without any sequelae 4 weeks after the accident. The endodontist was instructed to apply control medication (Lagricel; Sophia SA, Caracas, Venezuela) for 3 months and to return for ophthalmologic follow-up every 6 months. CONCLUSIONS: Sodium hypochlorite is an effective antibacterial irrigant indicated for the treatment of root canal infections. The tissue cytotoxicity highlights the need to inform the patient of the risk factors of accidents and enhance care with individual protection equipment for the patient and the professional during clinical procedures.
Asunto(s)
Quemaduras Químicas/etiología , Odontólogos , Quemaduras Oculares/inducido químicamente , Microcirugia/instrumentación , Enfermedades Profesionales/inducido químicamente , Irrigantes del Conducto Radicular/efectos adversos , Preparación del Conducto Radicular/instrumentación , Hipoclorito de Sodio/efectos adversos , Accidentes de Trabajo , Analgésicos no Narcóticos/uso terapéutico , Antibacterianos/uso terapéutico , Antiinflamatorios/uso terapéutico , Úlcera de la Córnea/inducido químicamente , Úlcera de la Córnea/tratamiento farmacológico , Ciclopentolato/uso terapéutico , Femenino , Fluoroquinolonas/uso terapéutico , Estudios de Seguimiento , Humanos , Ibuprofeno/uso terapéutico , Etabonato de Loteprednol/uso terapéutico , Moxifloxacino , Midriáticos/uso terapéutico , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Irrigación Terapéutica/métodos , Adulto JovenRESUMEN
PURPOSE: We described the change in visual acuity experienced by eyes successfully treated for bacterial keratitis. METHODS: This was a prospective cohort study of a subset of study participants who had previously enrolled in the Steroids for Corneal Ulcers Trial (SCUT). All study participants had been diagnosed with culture-proven bacterial keratitis before enrollment in SCUT and subsequently were randomized to adjunctive topical corticosteroids or placebo. During SCUT, we monitored study participants at enrollment, 3 weeks, 3 months, and 12 months. We invited a subset to complete a comprehensive eye examination approximately 4 years after enrollment in SCUT. Certified refractionists assessed best spectacle-corrected visual acuity (BSCVA) using the same protocol at each study visit. RESULTS: We examined 50 SCUT participants at 4 years after enrollment. Among those in this cohort, mean logMAR BSCVA at enrollment was 0.85 (Snellen equivalent, 20/160; 95% confidence interval [CI], 0.71-0.99). On average, visual acuity improved by 2.9 logMAR lines from enrollment to 3 weeks (P < 0.001), 1.2 lines from 3 weeks to 3 months (P = 0.002), and 0.8 lines from 3 to 12 months (P = 0.01). The BSCVA did not change significantly between 12 months and 4 years (0.04-line improvement, P = 0.88). After controlling for visual acuity at enrollment, BSCVA was not significantly different between the corticosteroid and placebo groups at 4 years (P = 0.53). CONCLUSIONS: Cases of bacterial keratitis may continue to demonstrate improvements in visual acuity up to 12 months following diagnosis, but further improvements are unlikely. These findings may guide the appropriate timing of surgical intervention in these patients. (ClinicalTrials.gov number, NCT00324168.).
Asunto(s)
Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Prednisolona/análogos & derivados , Adulto , Anciano , Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Úlcera de la Córnea/fisiopatología , Método Doble Ciego , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Fluoroquinolonas , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Prednisolona/uso terapéutico , Estudios Prospectivos , Quinolinas/uso terapéutico , Análisis de Regresión , Agudeza Visual/efectos de los fármacos , Agudeza Visual/fisiologíaAsunto(s)
Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Prednisolona/análogos & derivados , Recuperación de la Función/fisiología , Agudeza Visual/fisiología , Adulto , Anciano , Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Úlcera de la Córnea/microbiología , Úlcera de la Córnea/fisiopatología , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Prednisolona/uso terapéutico , Quinolinas/uso terapéuticoRESUMEN
Niosomes embodying ethanol and minimum amount of cholesterol (ethoniosomes) could be promising ocular delivery systems for water soluble and insoluble drugs. This manuscript reports on novel nano-sized elastic niosomes (ethoniosomes) composed of Span 60: cholesterol (7:3 mol/mol) and ethanol, for ocular delivery of prednisolone acetate (Pred A) and prednisolone sodium phosphate (Pred P). These ethoniosomes were prepared with the thin film hydration (TFH) and ethanol injection (EI) methods, characterized for percentage entrapment efficiency (% EE), size, zeta potential, morphology, elasticity, in vitro release and physical stability. Ocular irritation, bioavailability and anti-inflammatory effects were evaluated and compared with the conventional suspension and solution eye drops. The prepared ethoniosomal vesicles (EV) had a Z-average diameter of 267 nm, zeta potential of approximately -40 mV and % change in size after extrusion of 4%. They were physically stable for at least 2 months at 4 °C. The prepared EV showed good ocular tolerability using the modified Draize's test and the estimated relative ocular bioavailability for Pred A EV and Pred P EV was 1.54 and 1.75 times greater than that for the suspension and solution eye drops, respectively. The time required for complete healing from the clove oil-induced severe ocular inflammation was reduced to half with Pred A and Pred P EV. More interestingly, the intraocular pressure (IOP) elevation side effect recorded for Pred A and Pred P EV was significantly less than that for the conventional suspension and solution eye drops.
Asunto(s)
Antiinflamatorios/administración & dosificación , Endoftalmitis/tratamiento farmacológico , Liposomas/síntesis química , Prednisolona/análogos & derivados , Animales , Disponibilidad Biológica , Química Farmacéutica , Aceite de Clavo , Composición de Medicamentos , Estabilidad de Medicamentos , Elasticidad , Endoftalmitis/inducido químicamente , Etanol/química , Tamaño de la Partícula , Prednisolona/administración & dosificación , ConejosRESUMEN
PURPOSE: To determine whether topical corticosteroids as adjunctive therapy for bacterial keratitis improves long-term clinical outcomes. DESIGN: Randomized, placebo-controlled, double-masked clinical trial. METHODS: This multicenter trial compared 1.0% prednisolone sodium phosphate to placebo in the treatment of bacterial keratitis among 500 patients with culture-positive ulcers receiving 48 hours of moxifloxacin before randomization. The primary endpoint was 3 months from enrollment, and 399 patients were evaluated at 12 months. The outcomes examined were best spectacle-corrected visual acuity (BSCVA) and scar size at 12 months. Based on previous results, regression models with adjustments for baseline status and/or causative organism were used for analysis. RESULTS: No significant differences in clinical outcomes by treatment group were seen with the prespecified regression models (BSCVA: -0.04 logMAR, 95% CI, -0.12 to 0.05, P = .39; scar size: 0.03 mm, 95% CI, -0.12 to 0.18, P = .69). A regression model including a Nocardia-treatment arm interaction found corticosteroid use associated with a mean 1-line improvement in BSCVA at 12 months among patients with non-Nocardia ulcers (-0.10 logMAR, 95% CI, -0.19 to -0.02, P = .02). No significant difference was observed in 12-month BSCVA for Nocardia ulcers (0.18 logMAR, 95% CI, -0.04 to 0.41, P = .16). Corticosteroids were associated with larger mean scar size at 12 months among Nocardia ulcers (0.47 mm, 95% CI, 0.06-0.88, P = .02) and no significant difference was identified by treatment for scar size for non-Nocardia ulcers (-0.06 mm, 95% CI, -0.21 to 0.10, P = .46). CONCLUSIONS: Adjunctive topical corticosteroid therapy may be associated with improved long-term clinical outcomes in bacterial corneal ulcers not caused by Nocardia species.
Asunto(s)
Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Nocardiosis/tratamiento farmacológico , Prednisolona/análogos & derivados , Quinolinas/uso terapéutico , Administración Tópica , Adulto , Bacterias/aislamiento & purificación , Úlcera de la Córnea/microbiología , Método Doble Ciego , Infecciones Bacterianas del Ojo/microbiología , Femenino , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Nocardia/aislamiento & purificación , Nocardiosis/microbiología , Soluciones Oftálmicas , Prednisolona/uso terapéutico , Resultado del Tratamiento , Agudeza Visual/fisiologíaRESUMEN
PURPOSE: To describe temporal trends in Pseudomonas aeruginosa resistance to moxifloxacin in keratitis isolates from South India. METHODS: The Steroids for Corneal Ulcers Trial (SCUT) was a randomized, double-masked, placebo-controlled trial assessing outcomes in patients with culture positive bacterial corneal ulcers randomized to receive prednisolone phosphate or placebo. All patients received moxifloxacin, and susceptibility to moxifloxacin was measured at baseline using Etest. We investigated trends in moxifloxacin susceptibility of P. aeruginosa during 2007, 2008, and 2009 isolated in SCUT in South India. RESULTS: There were 89 P. aeruginosa isolates during 2007, 2008, and 2009 in SCUT that were eligible for this study. There was an increase in the proportion of resistant isolates from 19% in 2007 to 52% in 2009 (p = 0.02, χ(2) test for trend). Logistic regression showed that there was a 2-fold increase in odds of resistance per 1 year increase during the study period (odds ratio 2.16, 95% confidence interval 1.09-4.26, p = 0.027). CONCLUSIONS: We found a sharp increase in the proportion of isolates that were resistant to moxifloxacin from 2007 to 2009. Further work needs to be done to characterize the nature of this increase.
Asunto(s)
Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Enfermedades Transmisibles Emergentes , Úlcera de la Córnea/microbiología , Farmacorresistencia Bacteriana , Infecciones Bacterianas del Ojo/microbiología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/aislamiento & purificación , Quinolinas/uso terapéutico , Córnea/microbiología , Úlcera de la Córnea/tratamiento farmacológico , Método Doble Ciego , Quimioterapia Combinada , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Fluoroquinolonas , Glucocorticoides/uso terapéutico , Humanos , India , Pruebas de Sensibilidad Microbiana , Moxifloxacino , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacosRESUMEN
BACKGROUND: It has been recently reported that local injection of autologous blood in tennis elbow offers a significant benefit by virtue of various growth factors contained therein. The objective of our study was assessment of efficacy of autologous blood injection versus local corticosteroid injection in the treatment of tennis elbow. METHODS AND TRIAL DESIGN: A single blinded, prospective parallel group trial was undertaken. 50 consecutive patients of untreated lateral epicondylitis were enrolled. Randomisation was done on alternate basis and two groups were constituted, first one receiving steroid injection and second one injection of autologous blood. Both groups were evaluated at 2 and 6 weeks for pain relief and stage of disease. RESULTS: Baseline evaluation showed no difference between the two groups (chi square test, P > 0.05). Between group analysis at 2 weeks showed no difference in pain relief and Nirschl stage (unpaired t test, P > 0.05). Evaluation at 6 weeks demonstrated a significant decrease in pain levels and stage of disease in blood group (unpaired t test, p < 0.05). CONCLUSIONS: Autologous blood injection was more effective than steroid injection in the short term follow up in tennis elbow.
Asunto(s)
Transfusión de Sangre Autóloga/métodos , Glucocorticoides/uso terapéutico , Prednisolona/análogos & derivados , Codo de Tenista/terapia , Adulto , Femenino , Glucocorticoides/administración & dosificación , Humanos , Inyecciones Intraarticulares , Masculino , Persona de Mediana Edad , Dolor/etiología , Dimensión del Dolor , Prednisolona/administración & dosificación , Prednisolona/uso terapéutico , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Método Simple Ciego , Codo de Tenista/complicaciones , Codo de Tenista/tratamiento farmacológico , Resultado del TratamientoRESUMEN
OBJECTIVE: To analyze the relationship between fluoroquinolone use at presentation and minimum inhibitory concentration in bacterial keratitis. METHODS: The Steroids for Corneal Ulcers Trial was a randomized, double-masked, placebo-controlled trial assessing the effect of adjunctive topical corticosteroid treatment on outcomes in bacterial keratitis. After presentation, all patients were treated with moxifloxacin hydrochloride, 0.5%. We compare antibiotic use at presentation with minimum inhibitory concentration against moxifloxacin for all isolates. Separate analyses accounted for organism species and fluoroquinolone generation. RESULTS: Topical fluoroquinolone use at presentation was reported in 92 of 480 cases (19.2%). Causative organisms in the 480 cases included Streptococcus pneumoniae (247 cases [51.5%]), Pseudomonas aeruginosa (109 cases [22.7%]), and Nocardia species (55 cases [11.5%]). Isolates from patients who reported fluoroquinolone use at presentation had a 2.01-fold-higher minimum inhibitory concentration (95% CI, 1.39-fold to 2.91-fold; P < .001). Fourth-generation fluoroquinolones were associated with a 3.48-fold-higher minimum inhibitory concentration than those isolates that were not exposed to pretreatment at enrollment (95% CI, 1.99-fold to 6.06-fold; P < .001). CONCLUSION: This study provides evidence that prior use of fluoroquinolones is associated with antibiotic resistance. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00324168.
Asunto(s)
Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Bacterias/efectos de los fármacos , Úlcera de la Córnea/microbiología , Farmacorresistencia Bacteriana , Infecciones Bacterianas del Ojo/microbiología , Quinolinas/uso terapéutico , Adulto , Úlcera de la Córnea/tratamiento farmacológico , Método Doble Ciego , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Femenino , Fluoroquinolonas , Glucocorticoides/uso terapéutico , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Moxifloxacino , Nocardia/efectos de los fármacos , Nocardiosis/tratamiento farmacológico , Nocardiosis/microbiología , Infecciones Neumocócicas/tratamiento farmacológico , Infecciones Neumocócicas/microbiología , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , Streptococcus pneumoniae/efectos de los fármacosAsunto(s)
Antineoplásicos Fitogénicos/efectos adversos , Enfermedades de la Córnea/inducido químicamente , Podofilino/efectos adversos , Administración Tópica , Adulto , Enfermedades de la Córnea/tratamiento farmacológico , Dolor Ocular/inducido químicamente , Dolor Ocular/tratamiento farmacológico , Neoplasias de los Párpados/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Humanos , Masculino , Papiloma/tratamiento farmacológico , Fotofobia/inducido químicamente , Fotofobia/tratamiento farmacológico , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Trastornos de la Visión/inducido químicamente , Trastornos de la Visión/tratamiento farmacológico , Agudeza Visual/fisiologíaRESUMEN
PURPOSE: To elicit expert opinion on the use of adjunctive corticosteroid therapy in bacterial corneal ulcers. To perform a Bayesian analysis of the Steroids for Corneal Ulcers Trial (SCUT), using expert opinion as a prior probability. METHODS: The SCUT was a placebo-controlled trial assessing visual outcomes in patients receiving topical corticosteroids or placebo as adjunctive therapy for bacterial keratitis. Questionnaires were conducted at scientific meetings in India and North America to gauge expert consensus on the perceived benefit of corticosteroids as adjunct treatment. Bayesian analysis, using the questionnaire data as a prior probability and the primary outcome of SCUT as a likelihood, was performed. For comparison, an additional Bayesian analysis was performed using the results of the SCUT pilot study as a prior distribution. RESULTS: Indian respondents believed there to be a 1.21 Snellen line improvement, and North American respondents believed there to be a 1.24 line improvement with corticosteroid therapy. The SCUT primary outcome found a non-significant 0.09 Snellen line benefit with corticosteroid treatment. The results of the Bayesian analysis estimated a slightly greater benefit than did the SCUT primary analysis (0.19 lines verses 0.09 lines). CONCLUSION: Indian and North American experts had similar expectations on the effectiveness of corticosteroids in bacterial corneal ulcers; that corticosteroids would markedly improve visual outcomes. Bayesian analysis produced results very similar to those produced by the SCUT primary analysis. The similarity in result is likely due to the large sample size of SCUT and helps validate the results of SCUT.
Asunto(s)
Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Prednisolona/análogos & derivados , Agudeza Visual/efectos de los fármacos , Administración Tópica , Antiinfecciosos/uso terapéutico , Compuestos Aza/uso terapéutico , Teorema de Bayes , Úlcera de la Córnea/microbiología , Método Doble Ciego , Infecciones Bacterianas del Ojo/microbiología , Fluoroquinolonas , Humanos , Moxifloxacino , Soluciones Oftálmicas , Prednisolona/uso terapéutico , Quinolinas/uso terapéutico , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
PURPOSE: To compare the clinical course of Nocardia species keratitis with keratitis resulting from other bacterial organisms and to assess the effect of corticosteroids as adjunctive therapy using data collected from the Steroids for Corneal Ulcers Trial. DESIGN: Subgroup analysis of a randomized controlled trial. METHODS: setting: Multicenter randomized controlled trial. study population: Five hundred patients with bacterial keratitis randomized 1:1 to topical corticosteroid or placebo who had received at least 48 hours of topical moxifloxacin. intervention/observation procedure: Topical prednisolone phosphate 1% or placebo and clinical course of Nocardia keratitis. main outcome measures: Best spectacle-corrected visual acuity and infiltrate or scar size at 3 months from enrollment. RESULTS: Of 500 patients enrolled in the trial, 55 (11%) had a Nocardia corneal ulcer. Patients with Nocardia ulcers had better presentation visual acuity compared with non-Nocardia ulcers (median Snellen visual acuity, 20/45, compared with 20/145; P < .001) and comparable 3-month visual acuity (median, 20/25, vs 20/40; P = .25). Nocardia ulcers had approximately 2 lines less of improvement in visual acuity compared with non-Nocardia ulcers (0.21 logarithm of the minimal angle of resolution; 95% confidence interval, 0.09 to 0.33 logarithm of the minimal angle of resolution; P = .001). This difference may reflect the better starting visual acuity in patients with Nocardia ulcers. In Nocardia ulcers, corticosteroids were associated with an average 0.4-mm increase in 3-month infiltrate or scar size (95% confidence interval, 0.03 to 0.77 mm; P = .03). CONCLUSIONS: Nocardia ulcers responded well to treatment. They showed less overall improvement in visual acuity than non-Nocardia ulcers, but had better presentation acuity. Corticosteroids may be associated with worse outcomes.
Asunto(s)
Antiinfecciosos/uso terapéutico , Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Nocardiosis/tratamiento farmacológico , Nocardia/aislamiento & purificación , Administración Tópica , Adulto , Antiinfecciosos/administración & dosificación , Compuestos Aza/administración & dosificación , Compuestos Aza/uso terapéutico , Úlcera de la Córnea/diagnóstico , Úlcera de la Córnea/microbiología , Método Doble Ciego , Infecciones Bacterianas del Ojo/diagnóstico , Infecciones Bacterianas del Ojo/microbiología , Femenino , Fluoroquinolonas , Glucocorticoides/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Nocardia/genética , Nocardiosis/diagnóstico , Nocardiosis/microbiología , Reacción en Cadena de la Polimerasa , Prednisolona/administración & dosificación , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Quinolinas/administración & dosificación , Quinolinas/uso terapéutico , Resultado del Tratamiento , Agudeza Visual/fisiologíaRESUMEN
OBJECTIVES: To provide comprehensive trial methods and baseline data for the Steroids for Corneal Ulcers Trial and to present epidemiological characteristics such as risk factors, causative organisms, and ulcer severity. METHODS: Baseline data from a 1:1 randomized, placebo-controlled, double-masked clinical trial comparing prednisolone phosphate, 1%, with placebo as adjunctive therapy for the treatment of bacterial corneal ulcers. Eligible patients had a culture-positive bacterial corneal ulcer and had been taking moxifloxacin for 48 hours. The primary outcome for the trial is best spectacle-corrected visual acuity at 3 months from enrollment. This report provides comprehensive baseline data, including best spectacle-corrected visual acuity, infiltrate size, microbiological results, and patient demographics, for patients enrolled in the trial. RESULTS: Of 500 patients enrolled, 97% were in India. Two hundred twenty patients (44%) were agricultural workers. Median baseline visual acuity was 0.84 logMAR (Snellen, 20/125) (interquartile range, 0.36-1.7; Snellen, 20/50 to counting fingers). Baseline visual acuity was not significantly different between the United States and India. Ulcers in India had larger infiltrate/scar sizes (P = .04) and deeper infiltrates (P = .04) and were more likely to be localized centrally (P = .002) than ulcers enrolled in the United States. Gram-positive bacteria were the most common organisms isolated from the ulcers (n = 366, 72%). CONCLUSIONS: The Steroids for Corneal Ulcers Trial will compare the use of a topical corticosteroid with placebo as adjunctive therapy for bacterial corneal ulcers. Patients enrolled in this trial had diverse ulcer severity and on average significantly reduced visual acuity at presentation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00324168.